The Real Brokerage to Present at Upcoming Investor Conferences
Get Alerts REAX Hot Sheet
Join SI Premium – FREE
TORONTO & NEW YORK--(BUSINESS WIRE)-- The Real Brokerage Inc. (NASDAQ: REAX), the fastest growing publicly traded real estate brokerage, today announced that its Chairman and Chief Executive Officer, Tamir Poleg, will present at the following investor conferences:
Stephens Annual Investment Conference:
Date: Tuesday, November 14, 2023
Time: 2:00 p.m. ET (1:00 p.m. CT)
Webcast link: https://wsw.com/webcast/stph34/reax/1832544
Needham 3rd Annual Consumer Tech / E-commerce Virtual Conference:
Date: Monday, November 20, 2023
Time: 12:00 p.m. ET
Webcast link: https://wsw.com/webcast/needham137/reax/2256336
Real's remarks will be broadcast live and a replay will be available for one year at the links below, and by visiting the “Investors” section of www.onereal.com.
About Real
Real (NASDAQ: REAX) is a real estate experience company working to make life’s most complex transaction simple. The fast-growing company combines essential real estate, mortgage and closing services with powerful technology to deliver a single seamless end-to-end consumer experience, guided by trusted agents. With a presence throughout the U.S. and Canada, Real supports more than 12,000 agents who use its digital brokerage platform and tight-knit professional community to power their own forward-thinking businesses. Additional information can be found on its website at www.onereal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231109984430/en/
For additional information, please contact:
Ravi Jani
Vice President, Investor Relations and Financial Planning & Analysis
[email protected]
908.280.2515
For media inquiries, please contact:
Elisabeth Warrick
Senior Director, Marketing, Communications & Brand
[email protected]
201.564.4221
Source: The Real Brokerage Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European
- Esthetics Center Reaches 30-Year Milestone Across 4 Locations
- Laser Center of Marin Highlights Physician Oversight in August
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share